GIPL vs ZTS vs CHWY Stock Comparison

Global Innovative Platforms, Zoetis and Chewy Prices as of Oct 28, 2026 Peers: Industry group
ZTS Zoetis Inc.
$78.79 +12.0% 1M -45.3% 1Y
Market cap
$32.63B
P/E
12.6x
Revenue (TTM)
$9.52B
Div. yield
2.65%
Animal Health Healthcare
7 wins
CHWY Chewy, Inc.
$20.84 +14.1% 1M -37.9% 1Y
Market cap
$8.37B
P/E
30.9x
Revenue (TTM)
$13.07B
Div. yield
–
Packaged Foods Consumer Staples
2 wins

Head to Head

10 decided of 12

Zoetis leads on 7 of the 12 questions below (Zoetis 7, Chewy 2, Global Innovative Platforms 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGIPLZTSCHWYLeader
Larger companyMarket capitalisation $24.88M $32.63B $8.37B ZTS
Cheaper on earningsLower P/E, profitable companies only -36.0x 12.6x 30.9x ZTS
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 13.4x 27.4x ZTS
Faster revenue growthRevenue growth, trailing twelve months — +1.5% +5.9% CHWY
More profitableNet margin, trailing twelve months -361.7% 27.5% 2.1% ZTS
Better return on capitalReturn on invested capital — 23.4% — –
Less leveragedLower net debt / EBITDA 0.4x 1.8x 0.0x CHWY
Higher dividend yieldTrailing dividend yield — 2.65% — –
Better 1-year returnPrice return, last 12 months -37.5% -45.3% -37.9% GIPL
Better 5-year returnAnnualised price return, 5 years -36.9%/yr -18.3%/yr -22.8%/yr ZTS
Less volatileAnnualised volatility, 1 year 270.9% 40.6% 47.3% ZTS
Higher overall scoreMean of the five percentile scores vs peers 55/100 72/100 68/100 ZTS

Percentile Scorecard

GIPLZTSCHWY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGIPLZTSCHWY
Valuation 62 #237 of 624 88 #75 of 624 57 #20 of 45
Growth 27 #438 of 601 52 #289 of 601 90 #5 of 42
Profitability 40 #327 of 541 96 #22 of 541 56 #18 of 40
Financial Health 98 #12 of 647 34 #428 of 647 59 #20 of 47
Shareholder Returns 50 #181 of 359 89 #39 of 359 80 #7 of 31
Overall 55 72 68
  • GIPL ranked among 671 companies in Pharmaceuticals and Biotechnology
  • ZTS ranked among 671 companies in Pharmaceuticals and Biotechnology
  • CHWY ranked among 48 companies in Branded Foods

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGIPLZTSCHWYSPY
1 month 0.0%+12.0%+14.1% +0.7%
3 months 0.0%+3.6%-8.8% +3.7%
6 months -3.8%-31.5%-18.0% +7.1%
Year to date +354.5%-37.4%-36.9% +12.8%
1 year -37.5%-45.3%-37.9% +11.9%
3 years -52.4%-49.8%+12.2% +85.2%
3 years, per year -21.9%-20.5%+3.9% +22.8%
5 years -90.0%-63.6%-72.5% +67.6%
5 years, per year -36.9%-18.3%-22.8% +10.9%
10 years -79.2%+62.3%— +262.0%
10 years, per year -14.5%+5.0%— +13.7%

Risk

MeasureGIPLZTSCHWYSPY
Volatility, 1Y 270.9%40.6%47.3% 12.7%
Downside volatility, 1Y —49.4%48.2% 12.6%
Beta vs S&P 500, 1Y 2.260.520.77 1.00
Return / volatility, 1Y -0.14-1.11-0.80 0.94
Max drawdown, 5Y -98.0%-72.0%-81.2% -25.4%
From 52-week high -49.5%-45.4%-41.1% -1.2%
52-week high $0.99$144.35$35.37 $779.14
52-week low $0.11$69.12$17.51 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGIPLZTSCHWY
P/E now vs peer median -36.0xmedian 17.8x 12.6xmedian 17.8x 30.9xmedian 18.4x
P/S now vs peer median 132.9xmedian 9.1x 3.4xmedian 9.1x 0.6xmedian 0.7x
EV/EBITDA now vs peer median -39.5xmedian 15.0x 9.8xmedian 15.0x 17.7xmedian 12.0x
P/FCF now vs peer median -32.5xmedian 21.7x 14.1xmedian 21.7x 14.7xmedian 13.6x
P/B now vs peer median 46.8xmedian 2.2x 10.4xmedian 2.2x 22.6xmedian 1.6x
PEG now vs peer median -0.57median 0.35 1.34median 0.35 0.40median 0.55

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGIPLZTSCHWY
Revenue $187.20K $9.52B $13.07B
Gross profit – $6.81B $3.91B
Operating income -$677.04K $3.59B $328.20M
Net income -$677.04K $2.62B $273.70M
Free cash flow -$766.04K $2.32B $568.10M
R&D $377.99K $722.00M –
EPS (diluted) $-0.02 $6.26 $0.67
Cash & equivalents $244.24K $1.48B $611.00M
Total debt $8.62K $9.05B $591.70M
Shares (diluted) 44.54M 417.70M 410.10M
Enterprise value $24.27M $24.48B $5.65B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGIPLZTSCHWY
P/E -36.0x 12.6x 30.9x
P/FCF -32.5x 14.1x 14.7x
P/Operating cash flow -35.0x 11.5x 11.7x
P/S 132.9x 3.4x 0.6x
P/B 46.8x 10.4x 22.6x
P/Tangible book 47.1x 14.6x 37.9x
EV/EBITDA -39.5x 9.8x 17.7x
EV/EBIT -36.4x 11.1x 25.4x
EV/Revenue 131.6x 4.2x 0.6x
EV/FCF -32.2x 17.3x 14.7x
EV/Operating cash flow -34.7x 14.1x 11.6x
PEG (3Y EPS CAGR) -0.57 1.34 0.40

Growth

14 metrics
MetricGIPLZTSCHWY
Revenue growth (1Y) – 1.5% 5.9%
Revenue CAGR (3Y) – 5.0% 6.4%
Gross profit growth (1Y) – 1.8% 7.6%
Gross profit CAGR (3Y) – 5.7% 8.5%
Operating income growth (1Y) -20.9% -0.1% 102.0%
Operating income CAGR (3Y) -51.6% 5.2% 139.1%
Net income growth (1Y) -20.9% 0.6% 81.1%
Net income CAGR (3Y) -51.6% 5.7% 73.8%
EPS growth (1Y) -9.8% 7.7% 89.2%
EPS CAGR (3Y) 63.5% 9.4% 76.8%
Operating cash flow growth (1Y) 15.8% -4.6% 17.3%
Operating cash flow CAGR (3Y) -96.8% 12.4% 10.9%
Free cash flow growth (1Y) 9.2% 2.1% 22.7%
Free cash flow CAGR (3Y) -101.8% 21.7% 18.6%

Profitability

14 metrics
MetricGIPLZTSCHWY
Gross margin – 71.5% 29.9%
EBITDA margin -333.4% 42.8% 3.6%
Operating margin -361.7% 37.7% 2.5%
Pretax margin -361.7% 34.4% 2.7%
Net margin -361.7% 27.5% 2.1%
FCF margin -409.2% 24.3% 4.3%
Operating cash flow margin -379.8% 29.8% 5.5%
Return on equity -120.8% 82.0% 68.9%
Return on assets -119.7% 17.3% 7.8%
Return on invested capital – 23.4% –
Return on capital employed -121.4% 27.5% 24.9%
Asset turnover 0.3x 0.6x 3.7x
Cash conversion (OCF / net income) 1.1x 1.1x 2.6x
Stock comp / revenue – 1.0% 2.3%

Financial Health

11 metrics
MetricGIPLZTSCHWY
Debt / assets 1.0% 60.0% 15.8%
Debt / equity 0.0x 2.9x 1.6x
Net debt / EBITDA 0.4x 1.8x 0.0x
Debt / FCF 0.0x 3.9x 1.0x
Liabilities / assets 1.4% 79.1% 90.1%
Equity / assets 98.6% 20.9% 9.9%
Interest coverage – 15.1x –
Current ratio 34.7x 3.1x 0.8x
Quick ratio 33.2x 1.6x 0.4x
Cash ratio 31.3x 0.8x 0.3x
Altman Z-score 1,908 4.76 4.71

Shareholder Returns

7 metrics
MetricGIPLZTSCHWY
Dividend yield – 2.7% –
Net buyback yield -3.2% 11.2% 6.1%
Shareholder yield -3.2% 13.8% 6.1%
Payout ratio (earnings) – 34.0% –
Payout ratio (FCF) – 38.4% –
Dividend growth (1Y) – 6.1% –
Dividend CAGR (3Y) – 10.9% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGIPLZTSCHWY
Forward P/E – 13.4xFY2026 27.4xFY2026
EPS, next fiscal year – $5.86FY2026 $0.76FY2026
EPS growth, next FY – -8.6%FY2026 +46.2%FY2026
EPS growth, the year after – +13.0% +47.4%
Revenue, next fiscal year – $9.57BFY2026 $12.87BFY2026
Revenue growth, next FY – +1.0%FY2026 +2.1%FY2026
Revenue growth, the year after – -7.9% +5.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGIPLZTSCHWY
Held by institutions – 94.7% 100.0%
Institutions holding – 1,417 511
Change in shares held, QoQ – -2.6% -0.4%
Institutions buying – 674 277
Institutions selling – 582 155
Buyers to sellers – 1.16 1.79

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GIPLZTSCHWY
GIPL 1.00 0.02 0.01
ZTS 0.02 1.00 0.20
CHWY 0.01 0.20 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GIPL, ZTS and CHWY?

Zoetis (ZTS) is the largest by market capitalisation: Global Innovative Platforms (GIPL) $24.88M, Zoetis (ZTS) $32.63B, Chewy (CHWY) $8.37B.

Which stock is cheaper, GIPL, ZTS and CHWY?

Zoetis (ZTS) trades on the lowest price-to-earnings ratio (Global Innovative Platforms (GIPL) -36.0x, Zoetis (ZTS) 12.6x, Chewy (CHWY) 30.9x). On next year's consensus earnings, Zoetis (ZTS) is cheapest (Zoetis (ZTS) 13.4x, Chewy (CHWY) 27.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Chewy (CHWY) grew revenue fastest over the trailing twelve months: Zoetis (ZTS) +1.5%, Chewy (CHWY) +5.9%.

Which company is more profitable?

Zoetis (ZTS) has the highest net margin (Global Innovative Platforms (GIPL) -361.7%, Zoetis (ZTS) 27.5%, Chewy (CHWY) 2.1%).

Which stock has performed better?

Over the past year Global Innovative Platforms (GIPL) returned the most: Global Innovative Platforms (GIPL) -37.5%, Zoetis (ZTS) -45.3%, Chewy (CHWY) -37.9%. Over five years, Zoetis (ZTS) compounded fastest (Global Innovative Platforms (GIPL) -36.9%/yr, Zoetis (ZTS) -18.3%/yr, Chewy (CHWY) -22.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Zoetis (ZTS) 2.65%. Global Innovative Platforms (GIPL) and Chewy (CHWY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Zoetis (ZTS) has been the steadiest (Global Innovative Platforms (GIPL) 270.9%, Zoetis (ZTS) 40.6%, Chewy (CHWY) 47.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GIPL, ZTS and CHWY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Zoetis (ZTS) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.